GILL PARKASH S has a total of 16 patent applications. Its first patent ever was published in 1996. It filed its patents most often in Canada, EPO (European Patent Office) and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are SHANGHAI SIDANSAI BIOTECHNOLOGY CO LTD, ADAPTIMMUNE LTD and CELLECTIS.
# | Country | Total Patents | |
---|---|---|---|
#1 | Canada | 4 | |
#2 | EPO (European Patent Office) | 4 | |
#3 | Australia | 3 | |
#4 | WIPO (World Intellectual Property Organization) | 3 | |
#5 | China | 1 | |
#6 | Hong Kong | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Microorganisms | |
#4 | Peptides | |
#5 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Gill Parkash S | 15 |
#2 | Masood Rizwan | 8 |
#3 | Liu Ren | 2 |
#4 | Rizwan Gill Parkash S Masood | 1 |
Publication | Filing date | Title |
---|---|---|
AU2006233188A1 | Pharmaceutical compositions and methods of treatment based on VEGF antisense oligonucleotides | |
AU2001229254B2 | Pharmaceutical compositions and methods of treatment based on VEGF antisense oligonucleotides | |
WO9820866A2 | Method of treating kaposi's sarcoma by vitamin-d3 receptor agonists | |
CA2189916A1 | A new regime for paclitaxel in kaposi's sarcoma patients |